MDM2
Summary: This gene encodes a nuclear-localized E3 ubiquitin ligase. The encoded protein can promote tumor formation by targeting tumor suppressor proteins, such as p53, for proteasomal degradation. This gene is itself transcriptionally-regulated by p53. Overexpression or amplification of this locus is detected in a variety of different cancers. There is a pseudogene for this gene on chromosome 2. Alternative splicing results in a multitude of transcript variants, many of which may be expressed only in tumor cells. [provided by RefSeq, Jun 2013].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| MDM2 proto-oncogene | MIM:164785 | Ensembl:ENSG00000135679 | HGNC:HGNC:6973 | PA30718 | 12q15 |
GO terms in MDM2
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| BP | IDA | GO:0000122 | negative regulation of transcription by RNA polymerase II |
| BP | IEA | GO:0001568 | blood vessel development |
| BP | IEA | GO:0001974 | blood vessel remodeling |
| BP | IEA | GO:0002027 | regulation of heart rate |
| BP | IEA | GO:0003181 | atrioventricular valve morphogenesis |
| BP | IEA | GO:0003203 | endocardial cushion morphogenesis |
| BP | IEA | GO:0003281 | ventricular septum development |
| BP | IEA | GO:0003283 | atrial septum development |
| BP | IDA | GO:0006511 | ubiquitin-dependent protein catabolic process |
| BP | IGI | GO:0006511 | ubiquitin-dependent protein catabolic process |
| BP | IMP | GO:0006511 | ubiquitin-dependent protein catabolic process |
| BP | IMP | GO:0006977 | DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest |
| BP | TAS | GO:0006977 | DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest |
| BP | IEA | GO:0007089 | traversing start control point of mitotic cell cycle |
| BP | TAS | GO:0008284 | positive regulation of cell proliferation |
| BP | IEA | GO:0010039 | response to iron ion |
| BP | IEA | GO:0010628 | positive regulation of gene expression |
| BP | IEA | GO:0010955 | negative regulation of protein processing |
| BP | IEA | GO:0010977 | negative regulation of neuron projection development |
| BP | IEA | GO:0016032 | viral process |
| BP | IDA | GO:0016567 | protein ubiquitination |
| BP | TAS | GO:0016579 | protein deubiquitination |
| BP | IEA | GO:0016925 | protein sumoylation |
| BP | IMP | GO:0018205 | peptidyl-lysine modification |
| BP | IDA | GO:0031648 | protein destabilization |
| BP | IMP | GO:0031648 | protein destabilization |
| BP | IEA | GO:0032026 | response to magnesium ion |
| BP | IDA | GO:0032436 | positive regulation of proteasomal ubiquitin-dependent protein catabolic process |
| BP | IDA | GO:0034504 | protein localization to nucleus |
| BP | TAS | GO:0036369 | transcription factor catabolic process |
| BP | IDA | GO:0042176 | regulation of protein catabolic process |
| BP | IEA | GO:0042220 | response to cocaine |
| BP | IEA | GO:0043154 | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process |
| BP | IEA | GO:0043278 | response to morphine |
| BP | IDA | GO:0043518 | negative regulation of DNA damage response, signal transduction by p53 class mediator |
| BP | IDA | GO:0045184 | establishment of protein localization |
| BP | IEA | GO:0045472 | response to ether |
| BP | IDA | GO:0045892 | negative regulation of transcription, DNA-templated |
| BP | IMP | GO:0045892 | negative regulation of transcription, DNA-templated |
| BP | IMP | GO:0045931 | positive regulation of mitotic cell cycle |
| BP | IEP | GO:0046677 | response to antibiotic |
| BP | IEA | GO:0046827 | positive regulation of protein export from nucleus |
| BP | IEA | GO:0048545 | response to steroid hormone |
| BP | IMP | GO:0051603 | proteolysis involved in cellular protein catabolic process |
| BP | IMP | GO:0051865 | protein autoubiquitination |
| BP | IEA | GO:0060411 | cardiac septum morphogenesis |
| BP | IDA | GO:0065003 | protein-containing complex assembly |
| BP | IEA | GO:0070301 | cellular response to hydrogen peroxide |
| BP | IDA | GO:0071157 | negative regulation of cell cycle arrest |
| BP | IEA | GO:0071301 | cellular response to vitamin B1 |
| BP | IEA | GO:0071312 | cellular response to alkaloid |
| BP | IEA | GO:0071363 | cellular response to growth factor stimulus |
| BP | IEA | GO:0071375 | cellular response to peptide hormone stimulus |
| BP | IEA | GO:0071391 | cellular response to estrogen stimulus |
| BP | IEP | GO:0071456 | cellular response to hypoxia |
| BP | IDA | GO:0071480 | cellular response to gamma radiation |
| BP | IEA | GO:0071494 | cellular response to UV-C |
| BP | IDA | GO:0072717 | cellular response to actinomycin D |
| BP | TAS | GO:1901796 | regulation of signal transduction by p53 class mediator |
| BP | IDA | GO:1901797 | negative regulation of signal transduction by p53 class mediator |
| BP | IMP | GO:1902254 | negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator |
| BP | IEA | GO:1904404 | response to formaldehyde |
| BP | IEA | GO:1904707 | positive regulation of vascular smooth muscle cell proliferation |
| BP | IEA | GO:1904754 | positive regulation of vascular associated smooth muscle cell migration |
| BP | IMP | GO:1990000 | amyloid fibril formation |
| BP | IEA | GO:1990785 | response to water-immersion restraint stress |
| CC | IDA | GO:0005634 | nucleus |
| CC | IMP | GO:0005634 | nucleus |
| CC | IDA | GO:0005654 | nucleoplasm |
| CC | TAS | GO:0005654 | nucleoplasm |
| CC | IDA | GO:0005730 | nucleolus |
| CC | IMP | GO:0005730 | nucleolus |
| CC | IMP | GO:0005737 | cytoplasm |
| CC | TAS | GO:0005829 | cytosol |
| CC | TAS | GO:0005886 | plasma membrane |
| CC | IDA | GO:0016604 | nuclear body |
| CC | TAS | GO:0030666 | endocytic vesicle membrane |
| CC | IDA | GO:0032991 | protein-containing complex |
| CC | IMP | GO:0032991 | protein-containing complex |
| CC | IEA | GO:0045202 | synapse |
| MF | IPI | GO:0002039 | p53 binding |
| MF | IDA | GO:0004842 | ubiquitin-protein transferase activity |
| MF | IMP | GO:0004842 | ubiquitin-protein transferase activity |
| MF | IPI | GO:0005515 | protein binding |
| MF | IDA | GO:0008097 | 5S rRNA binding |
| MF | IDA | GO:0008270 | zinc ion binding |
| MF | IDA | GO:0016874 | ligase activity |
| MF | EXP | GO:0019789 | SUMO transferase activity |
| MF | IPI | GO:0019899 | enzyme binding |
| MF | IPI | GO:0019904 | protein domain specific binding |
| MF | IPI | GO:0031625 | ubiquitin protein ligase binding |
| MF | IEA | GO:0033612 | receptor serine/threonine kinase binding |
| MF | IPI | GO:0042802 | identical protein binding |
| MF | IEA | GO:0042975 | peroxisome proliferator activated receptor binding |
| MF | IDA | GO:0043021 | ribonucleoprotein complex binding |
| MF | IPI | GO:0047485 | protein N-terminus binding |
| MF | IDA | GO:0061630 | ubiquitin protein ligase activity |
| MF | IMP | GO:0061630 | ubiquitin protein ligase activity |
| MF | TAS | GO:0061630 | ubiquitin protein ligase activity |
| MF | IMP | GO:0061663 | NEDD8 ligase activity |
| MF | IEA | GO:0097110 | scaffold protein binding |
| MF | IPI | GO:0097718 | disordered domain specific binding |
Gene expression in normal tissue: MDM2
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in MDM2
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| reactome | R-HSA-112314 | Neurotransmitter receptors and postsynaptic signal transmission |
| reactome | R-HSA-112315 | Transmission across Chemical Synapses |
| reactome | R-HSA-112316 | Neuronal System |
| reactome | R-HSA-1257604 | PIP3 activates AKT signaling |
| reactome | R-HSA-162582 | Signal Transduction |
| reactome | R-HSA-1640170 | Cell Cycle |
| reactome | R-HSA-1643685 | Disease |
| reactome | R-HSA-198323 | AKT phosphorylates targets in the cytosol |
| reactome | R-HSA-212436 | Generic Transcription Pathway |
| reactome | R-HSA-2219528 | PI3K/AKT Signaling in Cancer |
| reactome | R-HSA-2262752 | Cellular responses to stress |
| reactome | R-HSA-2559580 | Oxidative Stress Induced Senescence |
| reactome | R-HSA-2559583 | Cellular Senescence |
| reactome | R-HSA-2559585 | Oncogene Induced Senescence |
| reactome | R-HSA-2990846 | SUMOylation |
| reactome | R-HSA-3108232 | SUMO E3 ligases SUMOylate target proteins |
| reactome | R-HSA-3232118 | SUMOylation of transcription factors |
| reactome | R-HSA-3232142 | SUMOylation of ubiquitinylation proteins |
| reactome | R-HSA-3700989 | Transcriptional Regulation by TP53 |
| reactome | R-HSA-392499 | Metabolism of proteins |
| reactome | R-HSA-399719 | Trafficking of AMPA receptors |
| reactome | R-HSA-399721 | Glutamate binding, activation of AMPA receptors and synaptic plasticity |
| reactome | R-HSA-5633007 | Regulation of TP53 Activity |
| reactome | R-HSA-5663202 | Diseases of signal transduction |
| reactome | R-HSA-5674400 | Constitutive Signaling by AKT1 E17K in Cancer |
| reactome | R-HSA-5688426 | Deubiquitination |
| reactome | R-HSA-5689880 | Ub-specific processing proteases |
| reactome | R-HSA-597592 | Post-translational protein modification |
| reactome | R-HSA-6804756 | Regulation of TP53 Activity through Phosphorylation |
| reactome | R-HSA-6804757 | Regulation of TP53 Degradation |
| reactome | R-HSA-6804760 | Regulation of TP53 Activity through Methylation |
| reactome | R-HSA-6806003 | Regulation of TP53 Expression and Degradation |
| reactome | R-HSA-69541 | Stabilization of p53 |
| reactome | R-HSA-69563 | p53-Dependent G1 DNA Damage Response |
| reactome | R-HSA-69580 | p53-Dependent G1/S DNA damage checkpoint |
| reactome | R-HSA-69615 | G1/S DNA Damage Checkpoints |
| reactome | R-HSA-69620 | Cell Cycle Checkpoints |
| reactome | R-HSA-73857 | RNA Polymerase II Transcription |
| reactome | R-HSA-74160 | Gene expression (Transcription) |
| reactome | R-HSA-8878159 | Transcriptional regulation by RUNX3 |
| reactome | R-HSA-8941858 | Regulation of RUNX3 expression and activity |
| reactome | R-HSA-8953897 | Cellular responses to external stimuli |
| reactome | R-HSA-9006925 | Intracellular signaling by second messengers |
| biocarta | arfpathway | tumor suppressor arf inhibits ribosomal biogenesis |
| biocarta | atmpathway | atm signaling pathway |
| biocarta | ctcfpathway | ctcf: first multivalent nuclear factor |
| biocarta | g2pathway | cell cycle: g2/m checkpoint |
| biocarta | hivnefpathway | hiv-1 nef: negative effector of fas and tnf |
| biocarta | p53hypoxiapathway | hypoxia and p53 in the cardiovascular system |
| biocarta | p53pathway | p53 signaling pathway |
| biocarta | ranbp2pathway | sumoylation by ranbp2 regulates transcriptional repression |
| pid | ar_tf_pathway | Regulation of Androgen receptor activity |
| pid | atm_pathway | ATM pathway |
| pid | atr_pathway | ATR signaling pathway |
| pid | aurora_a_pathway | Aurora A signaling |
| pid | deltanp63pathway | Validated transcriptional targets of deltaNp63 isoforms |
| pid | erbb4_pathway | ErbB4 signaling events |
| pid | p53downstreampathway | Direct p53 effectors |
| pid | p53regulationpathway | p53 pathway |
| pid | p73pathway | p73 transcription factor network |
| pid | ranbp2pathway | Sumoylation by RanBP2 regulates transcriptional repression |
| pid | reg_gr_pathway | Glucocorticoid receptor regulatory network |
| pid | tap63pathway | Validated transcriptional targets of TAp63 isoforms |
| netpath | Pathway_AndrogenReceptor | AndrogenReceptor |
| kegg | hsa04068 | FoxO signaling pathway - Homo sapiens (human) |
| kegg | hsa04110 | Cell cycle - Homo sapiens (human) |
| kegg | hsa04115 | p53 signaling pathway - Homo sapiens (human) |
| kegg | hsa04120 | Ubiquitin mediated proteolysis - Homo sapiens (human) |
| kegg | hsa04144 | Endocytosis - Homo sapiens (human) |
| kegg | hsa04151 | PI3K-Akt signaling pathway - Homo sapiens (human) |
| kegg | hsa04218 | Cellular senescence - Homo sapiens (human) |
| kegg | hsa04625 | C-type lectin receptor signaling pathway - Homo sapiens (human) |
| kegg | hsa04919 | Thyroid hormone signaling pathway - Homo sapiens (human) |
| kegg | hsa05165 | Human papillomavirus infection - Homo sapiens (human) |
| kegg | hsa05169 | Epstein-Barr virus infection - Homo sapiens (human) |
| kegg | hsa05200 | Pathways in cancer - Homo sapiens (human) |
| kegg | hsa05202 | Transcriptional misregulation in cancer - Homo sapiens (human) |
| kegg | hsa05203 | Viral carcinogenesis - Homo sapiens (human) |
| kegg | hsa05205 | Proteoglycans in cancer - Homo sapiens (human) |
| kegg | hsa05206 | MicroRNAs in cancer - Homo sapiens (human) |
| kegg | hsa05214 | Glioma - Homo sapiens (human) |
| kegg | hsa05215 | Prostate cancer - Homo sapiens (human) |
| kegg | hsa05218 | Melanoma - Homo sapiens (human) |
| kegg | hsa05219 | Bladder cancer - Homo sapiens (human) |
| kegg | hsa05220 | Chronic myeloid leukemia - Homo sapiens (human) |
| wikipathways | WP138 | Androgen receptor signaling pathway |
| wikipathways | WP1530 | miRNA Regulation of DNA Damage Response |
| wikipathways | WP1742 | TP53 Network |
| wikipathways | WP179 | Cell Cycle |
| wikipathways | WP2261 | Signaling Pathways in Glioblastoma |
| wikipathways | WP2446 | Retinoblastoma (RB) in Cancer |
| wikipathways | WP2512 | Integrated Lung Cancer Pathway |
| wikipathways | WP254 | Apoptosis |
| wikipathways | WP2593 | JAK-STAT |
| wikipathways | WP2828 | Bladder Cancer |
| wikipathways | WP3286 | Copper homeostasis |
| wikipathways | WP3639 | Apoptotic Signaling Pathway |
| wikipathways | WP3807 | Regulation of TP53 Expression and Degradation |
| wikipathways | WP3931 | ESC Pluripotency Pathways |
| wikipathways | WP3932 | Focal Adhesion-PI3K-Akt-mTOR-signaling pathway |
| wikipathways | WP3981 | miRNA regulation of prostate cancer signaling pathways |
| wikipathways | WP3982 | miRNA regulation of p53 pathway in prostate cancer |
| wikipathways | WP4172 | PI3K-Akt Signaling Pathway |
| wikipathways | WP45 | G1 to S cell cycle control |
| wikipathways | WP465 | Tryptophan metabolism |
| wikipathways | WP615 | Senescence and Autophagy in Cancer |
| wikipathways | WP673 | ErbB Signaling Pathway |
| wikipathways | WP707 | DNA Damage Response |
| wikipathways | WP710 | DNA Damage Response (only ATM dependent) |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD499 | PDMP | 1 |
| iGMDRD352 | PD-0325901 | 1 |
| iGMDRD536 | PLX-4720 | 1 |
| iGMDRD85 | Ursolic acid | 1 |
| iGMDRD341 | Triacsin c | 3 |
| iGMDRD512 | nutlin 3 | 1 |
| iGMDRD84 | Lovastatin acid | 5 |
| iGMDRD79 | Gemcitabine | 2 |
| iGMDRD720 | 844499-71-4 | 1 |
| iGMDRD702 | SAR405838 | 1 |
| iGMDRD160 | Cis-Platin | 3 |
| iGMDRD299 | ICL 670 | 1 |
| iGMDRD886 | Compound 1541A | 5 |
| iGMDRD615 | BRD-K02251932 | 1 |
| iGMDRD5 | Tyrphostin AG 1478 | 2 |
| iGMDRD121 | GMX1778 | 3 |
| iGMDRD271 | Brefeldin A | 2 |
| iGMDRD103 | SN-38 | 2 |
| iGMDRD213 | SMR000068650 | 2 |
| iGMDRD152 | 179324-69-7 | 1 |
| iGMDRD61 | Kinetin riboside | 5 |
| iGMDRD201 | SKI II | 1 |
| iGMDRD446 | LY 2183240 | 2 |
| iGMDRD634 | SCHEMBL2608041 | 2 |
| iGMDRD198 | AC1LE7KD | 1 |
| iGMDRD136 | Nutlin-3 | 1 |
| iGMDRD97 | Bexarotene | 1 |
| iGMDRD483 | SCH-529074 | 2 |
| iGMDRD546 | BMS-754807 | 2 |
| iGMDRD779 | PRL-3 Inhibitor I | 3 |
| iGMDRD398 | Sepantronium | 2 |
| iGMDRD789 | DS-3032B | 1 |
| iGMDRD562 | Navitoclax | 1 |
| iGMDRD887 | Compound 23 citrate | 1 |
| iGMDRD399 | Selumetinib | 1 |
| iGMDRD100 | Zebularine | 7 |
| iGMDRD939 | MDM2 inhibitor (tumors TP53 wt) | 2 |
| iGMDRD356 | PNU-74654 | 1 |
| iGMDRD23 | Gossypol | 2 |
| iGMDRD190 | Nilotinib | 1 |
| iGMDRD260 | FQI-2 | 2 |
| iGMDRD474 | Avrainvillamide | 2 |
| iGMDRD309 | 17AAG | 1 |
| iGMDRD390 | MDM2 inhibitor | 2 |
| iGMDRD318 | PAC-1 | 1 |
| iGMDRD441 | TW 37 | 1 |
| iGMDRD284 | Palbociclib | 1 |
| iGMDRD171 | Pemetrexed | 1 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in MDM2
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.